2-phenyl-3-(4-phenyl-piperidin-1-ylmethyl)-quinoline-4-carboxylic acid hydrochloride | 270574-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-phenyl-3-(4-phenyl-piperidin-1-ylmethyl)-quinoline-4-carboxylic acid hydrochloride
• 英文别名: 2-phenyl-3-[(4-phenylpiperidin-1-yl)methyl]quinoline-4-carboxylic acid;hydrochloride
• CAS: 270574-07-7
• 化学式: C₂₈H₂₆N₂O₂*ClH
• 分子量: 458.988
• InChiKey: JJWKUUXBJHMMKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-phenyl-3-(4-phenyl-piperidin-1-ylmethyl)-quinoline-4-carboxylic acid hydrochloride 、 三乙胺 、 、 (S)-(-)-1-苯丙胺 在 水 、 sodium hydroxide 、 Brine 、 Sodium sulfate-III 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 2-Phenyl-3-(4-phenyl-piperidin-1-ylmethyl)-quinoline-4-carboxylic Acid ((S)-1-phenyl-propyl)-amide
  参考文献：
  名称：

  Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists

  摘要：

  公式（I）的化合物，溶剂化合物或盐，其中，Ar是可选取代的芳基或C5-7环戊二烯基团，或可选取代的C5-7环烷基团，或可选取代的单个或融合的芳香杂环基团；R是氢，线性或支链C1-6烷基，C3-7环烷基，C3-7环烷基烷基；R1表示氢或来自以下列表的最多三个可选取代基团之一：C1-6烷基，C1-6烯基，芳基，C1-6烷氧基，羟基，卤素，硝基，氰基，羧基，羧酰胺基，磺酰胺基，C1-6烷氧羰基，三氟甲基，酰氧基，氨基或单个和双C1-6烷基氨基；R2表示一个基团-（CH2）n-NY1Y2，其中n是整数1至9，Y1和Y2独立选择自C1-6烷基；C1-6烷基取代羟基，烷氧基，C1-6烷基氨基或双（C1-6烷基）氨基；C3-6环烷基；C4-6氮杂环烷基；C1-6烯基；芳基或芳基-C1-6烷基或Y1和Y2与它们连接的氮原子一起表示可选取代的N-连接的单个或融合的环杂环基团；R3是支链或线性C1-6烷基，C3-7环烷基，C4-7环烷基烷基，可选取代的芳基，或可选取代的单个或融合的芳香杂环基团；R4表示氢或C1-6烷基，R5表示氢或卤素；制备此类化合物的方法，包含此类化合物的制药组合物以及在医学上使用此类化合物和组合物的用途。

  公开号：

  US20030212101A1

文献信息

• Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
  申请人：SmithKline Beecham S.p.A.

  公开号：US20030212101A1

  公开（公告）日：2003-11-13

  A compound, or a solvate or a salt thereof, of formula (I): 1 wherein, Ar is an optionally substituted aryl or a C 5-7 cycloalkdienyl group, or an optionally substituted C 5-7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is hydrogen, linear or branched C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl; R 1 represents hydrogen or up to three optional substituents selected from the list consisting of: C 1-6 alkyl, C 1-6 alkenyl, aryl, C 1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C 1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-C 1-6 alkylamino; R 2 represents a moiety —(CH 2 ) n —NY 1 Y 2 wherein n is an integer in the range of from 1 to 9, Y 1 and Y 2 are independently selected from C 1-6 -alkyl; C 1-6 alkyl substituted with hydroxy, alkoxy, C 1-6 alkylamino or bis (C 1-6 alkyl) amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C 1-6 -alkenyl; aryl or aryl-C 1-6 -alkyl or Y 1 and Y 2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group; R 3 is branched or linear C 1-6 alkyl, C 3-7 cycloalkyl, C 4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R 4 represents hydrogen or C 1-6 alkyl, R 5 represents hydrogen or halogen; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  式（I）的化合物，或其溶剂化物或盐，其中，Ar是可选择取代的芳基或C5-7环烯基基团，或可选择取代的C5-7环烷基基团，或可选择取代的单环或融合环芳香杂环基团；R是氢，直链或支链的C1-6烷基，C3-7环烷烷基，C3-7环烷烷基烷基；R1代表氢或来自以下列表中选择的最多三个可选取代基：C1-6烷基，C1-6烯基，芳基，C1-6烷氧基，羟基，卤素，硝基，氰基，羧基，羧胺基，磺胺基，C1-6烷氧羰基，三氟甲基，酰氧基，氨基或单-和双-C1-6烷基氨基；R2代表一个基团—（CH2）n—NY1Y2，其中n是1到9范围内的整数，Y1和Y2独立选择自C1-6烷基；C1-6烷基取代羟基，烷氧基，C1-6烷基氨基或双（C1-6烷基）氨基；C3-6环烷基；C4-6氮杂环烷基；C1-6烯基；芳基或芳基-C1-6烷基或Y1和Y2与它们连接的氮原子一起代表一个可选择取代的N-连接的单环或融合环杂环基团；R3是支链或直链的C1-6烷基，C3-7环烷烷基，C4-7环烷烷基烷基，可选择取代的芳基，或可选择取代的单环或融合环芳香杂环基团；和R4代表氢或C1-6烷基，R5代表氢或卤素；制备这种化合物的过程，包括这种化合物的药物组合物以及这种化合物和组合物在医学中的用途。
• QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS
  申请人：Smithkline Beecham S.p.A.

  公开号：EP1131295A1

  公开（公告）日：2001-09-12
• US6780875B2
  申请人：——

  公开号：US6780875B2

  公开（公告）日：2004-08-24
• [EN] QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE QUINOLINE-4-CARBOXAMIDE UTILISES COMME ANTAGONISTES DES RECEPTEURS NK-3 ET NK-2
  申请人：SMITHKLINE BEECHAM SPA

  公开号：WO2000031037A1

  公开（公告）日：2000-06-02

  A compound, or a solvate or a salt thereof, of formula (I): wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted C5-7 cycloalkyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is hydrogen, linear or branched C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, R1 represents hydrogen or up to three optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono- and di-C1-6 alkylamino; R2 represents a moiety -(CH2)n-NY1Y2 wherein n is an integrer in the range of from 1 to 9, Y1 and Y2 are independently selected from C1-6- alkyl; C1-6 alkyl substituted with hydroxy, alkoxy, C1-6 alkylamino or bis (C1-6 alkyl)amino; C3-6 cycloalkyl; C4-6 azacycloalkyl; C1-6-alkenyl; aryl or aryl-C1-6-alkyl or Y1 and Y2 together with the nitrogen atom to which they are attached represent an optionally substituted N-linked single or fused ring heterocyclic group; R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or C1-6 alkyl, R5 represents hydrogen or halogen; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.